The schedule of administration of canakinumab in cryopyrin associated periodic syndrome is driven by the phenotype severity rather than the age.

doi:10.1186/ar4184

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

The schedule of administration of canakinumab in cryopyrin associated periodic syndrome is driven by the phenotype severity rather than the age.

Arthritis research & therapy - 26 Feb 2013

Caorsi Roberta, Lepore Loredana, Zulian Francesco, Alessio Maria, Stabile Achille, Insalaco Antonella, Finetti Martina, Battagliese Antonella, Martini Giorgia, Bibalo Chiara, Martini Alberto, Gattorno Marco

Abstract excerpt

INTRODUCTION: Interleukin-1 (IL-1) blockade is the treatment of choice of cryopyrin associated periodic syndromes (CAPS). Anti-IL-1 monoclonal antibody (canakinumab) was recently registered. However no clear data are available on the optimal schedule of administration of this drug. The aim of the present study was to analyse the impact of canakinumab on CAPS patients in daily clinical practice and to identify the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Age Factors
Share to Antibodies, Monoclonal

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Antibodies, Monoclonal, Humanized

Share to Cryopyrin-Associated Periodic Syndromes

Share to Follow-Up Studies

Share to Infant

Share to Infant, Newborn

Share to Treatment Outcome

Source

Open in PubMed Open full text

Identifiers

PMID: 23442610
DOI: 10.1186/ar4184
PMCID: PMC3672768

Genes

CAPS

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.